Webinars with Ovid Therapeutics about Clinical Trials of OV-101 in Angelman Syndrome

In 2016, Ovid Therapeutics, a privately held biopharmaceutical company announced its intention to conduct a clinical trial on Angelman syndrome.  After receiving Orphan Drug status for its drug, OV-101, Ovid opened the STARS Clinical Trial in 2017. 

Below are recordings of live webinars that Ovid Therapeutics participated in to address questions and concerns that arose from the time of the initial the announcement in 2016 to the conclusion of the STARS Trial and announcement of findings in August 2018. 

Recording from Webinar on Wednesday, August 23, 2018

Recording from Webinar on Wednesday, June 21, 2017

Recording from Webinar on Tuesday, October 4, 2016

Recording from Webinar on August 10, 2016